Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.

This trial is testing whether adding camrelizumab — an immunotherapy drug — to chemotherapy before surgery improves outcomes for patients with resectable (surgically removable) esophageal squamous cell carcinoma compared to chemoradiation alone. **You may be eligible if...** - You are between 18 and 75 years old with confirmed esophageal squamous cell cancer - Your cancer has not been previously treated - Your cancer is resectable (clinical stage T1b-T3 with lymph node involvement, or T3 without node involvement) - You are in good general health (ECOG 0–1) - Your major organ function is normal **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have had prior treatment for esophageal cancer - You have active autoimmune disease requiring treatment - You have significant heart or lung disease - You are pregnant or breastfeeding - You have active hepatitis B or C, or HIV Talk to your doctor to see if this trial is right for you.